The FDA has approved the first new Alzheimer’s treatment in more than two decades.
Aduhelm is the first drug ever authorized to slow the progression of Alzheimer’s disease. It works by removing the buildup of toxic proteins from the brain which are believed to be a key factor of the neurodegenerative disease.
The Ohio State University Wexner Medical Center has been involved in clinical trials for aduhelm from the start. Dr. Douglas Scharre, a neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, is available to discuss the impact the drug can have for the millions of Americans living with Alzheimer’s disease.